NeurAxis Announces New CPT Category I Code For Percutaneous Electrical Nerve Field Stimulation
Portfolio Pulse from Benzinga Newsdesk
NeurAxis, Inc. (NYSE:NRXS) announced a new CPT Category I code for its PENFS technology, IB-Stim, effective January 1, 2026. This FDA-cleared device addresses functional abdominal pain in adolescents with IBS, offering a non-drug alternative.
October 22, 2024 | 1:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
NeurAxis has announced a new CPT Category I code for its PENFS technology, IB-Stim, effective January 1, 2026. This development could enhance the adoption of IB-Stim, a non-surgical device for treating IBS-related pain in adolescents.
The new CPT Category I code is a significant regulatory milestone that could increase the adoption and reimbursement of NeurAxis' IB-Stim device. This is likely to positively impact the company's market position and stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100